Nunno V.D.; Mollica V.; Gatto L.; Santoni M.; Cosmai L.; Porta C.; Massari F., Prognostic impact of neutrophil-to-lymphocyte ratio in renal cell carcinoma: A systematic review and meta-analysis, «IMMUNOTHERAPY», 2019, 11, pp. 631 - 643 [Scientific article]
Saeed O.; Lopez-Beltran A.; Fisher K.W.; Scarpelli M.; Montironi R.; Cimadamore A.; Massari F.; Santoni M.; Cheng L., RAS genes in colorectal carcinoma: Pathogenesis, testing guidelines and treatment implications, «JOURNAL OF CLINICAL PATHOLOGY», 2019, 72, pp. 135 - 139 [Scientific article]
Massari F.; Di Nunno V.; Santoni M., Re: Arnaud Méjean, Alain Ravaud, Simon Thezenas, et al. Sunitinib Alone or After Nephrectomy in Metastatic Renal-cell Carcinoma. N Engl J Med 2018;379:417–27: CARMENA Trial: Is This the End of Cytoreductive Nephrectomy in Patients with Clear-cell Renal Cell Carcinoma?, «EUROPEAN UROLOGY ONCOLOGY», 2019, 2, pp. 340 - 341 [Scientific article]
Massari F.; Di Nunno V.; Santoni M.; Gatto L.; Mollica V.; Porta C., Re: Bimal Bhindi, E. Jason Abel, Laurence Albiges, et al. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. Eur Urol 2019;75:111-28: Cytoreductive Nephrectomy in the Targeted Therapy Era: This is Not the End, «EUROPEAN UROLOGY ONCOLOGY», 2019, 2, pp. 603 - 604 [Scientific article]
Santoni M.; Montironi R.; Battelli N.; Massari F., Reply to Michael Staehler, Dena Battle, Axel Bex, Hans Hammers, and Daniel George's Letter to the Editor re: Arnaud Méjean, Alain Ravaud, Simon Thezenas, et al. Sunitinib Alone or After Nephrectomy in Metastatic Renal-cell Carcinoma. Eur Urol 2018;74:842–3: Lymphocyte Phenotype and Timing of Radical Nephrectomy in Patients Treated with Immunocheckpoint Inhibitors for Renal Cell Carcinoma, «EUROPEAN UROLOGY», 2019, 75, pp. 64 - 66 [Scientific article]
Mollica V.; Di Nunno V.; Gatto L.; Santoni M.; Scarpelli M.; Cimadamore A.; Lopez-Beltran A.; Cheng L.; Battelli N.; Montironi R.; Massari F., Resistance to systemic agents in renal cell carcinoma predict and overcome genomic strategies adopted by tumor, «CANCERS», 2019, 11, Article number: 830 , pp. 1 - 16 [Scientific article]Open Access
Prisciandaro M.; Ratta R.; Massari F.; Fornarini G.; Caponnetto S.; Iacovelli R.; De Giorgi U.; Facchini G.; Scagliarini S.; Sabbatini R.; Caserta C.; Peverelli G.; Mennitto A.; Verzoni E.; Procopio G., Safety and efficacy of cabozantinib for metastatic nonclear renal cell carcinoma: Real-world data from an Italian managed access program, «AMERICAN JOURNAL OF CLINICAL ONCOLOGY: CANCER CLINICAL TRIALS», 2019, 42, pp. 42 - 45 [Scientific article]
Santoni M.; Conti A.; Massari F.; Di Nunno V.; Faloppi L.; Galizia E.; Morbiducci J.; Piva F.; Buti S.; Iacovelli R.; Ferretti B.; Cimadamore A.; Scarpelli M.; Lopez-Beltran A.; Cheng L.; Battelli N.; Montironi R., Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies, «EXPERT REVIEW OF CARDIOVASCULAR THERAPY», 2019, 17, pp. 917 - 927 [Scientific article]
Iacovelli R.; Galli L.; De Giorgi U.; Porta C.; Nole F.; Zucali P.; Sabbatini R.; Mosca A.; Atzori F.; Santini D.; Facchini G.; Fornarini G.; Buti S.; Massari F.; Masini C.; Ricotta R.; Biasco E.; Lolli C.; Gri N.; Verri E.; Miggiano C.; Vitale M.G.; Tortora G., The effect of a treatment delay on outcome in metastatic renal cell carcinoma, «UROLOGIC ONCOLOGY», 2019, 37, pp. 529 - 535 [Scientific article]
Massari, F.; Mollica, V.; Di Nunno, V.; Gatto, L.; Santoni, M.; Scarpelli, M.; Cimadamore, A.; Lopez-Beltran, A.; Cheng, L.; Battelli, N.; Montironi, R.; Brandi, G., The human microbiota and prostate cancer: Friend or foe?, «CANCERS», 2019, 11, Article number: 459 , pp. 459 - 469 [Scientific article]Open Access
Massari F.; Di Nunno V.; Santoni M.; Gatto L.; Caserta C.; Morelli F.; Zafarana E.; Carrozza F.; Mosca A.; Mollica V.; Iacovelli R.; Sabbatini R.; Porta C.; Bracarda S., Toward a genome-based treatment landscape for renal cell carcinoma, «CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY», 2019, 142, pp. 141 - 152 [Scientific article]
Boni G, Mazzarri S, Cianci C, Galli L, Farnesi A, Borsatti E, Bortolus R, Fratino L, Gobitti C, Lamaj E, Ghedini P, Rizzini EL, Massari F, Dionisi V, Fanti S, Volterrani D, Monari F., 223Ra-chloride therapy in men with hormone-refractory prostate cancer and skeletal metastases: Real-world experience., «TUMORI», 2018, 104(2), pp. 128 - 136 [Scientific article]
Mollica V, Di Nunno V, Corcioni B, Fiorentino M, Nobili E, Schiavina R, Golfieri R, Brunocilla E, Ardizzoni A, Massari F, A case of complete response to nivolumab after long-term progression-free survival with tyrosine kinase inhibitor., «ANTI-CANCER DRUGS», 2018, 29, pp. 911 - 913 [Scientific article]
Massari F.; Santoni M.; di Nunno V.; Cheng L.; Lopez-Beltran A.; Cimadamore A.; Gasparrini S.; Scarpelli M.; Battelli N.; Montironi R., Adjuvant and neoadjuvant approaches for urothelial cancer: Updated indications and controversies, «CANCER TREATMENT REVIEWS», 2018, 68, pp. 80 - 85 [Scientific article]
Massari F.; Di Nunno V., Atezolizumab for platinum-treated metastatic urothelial carcinoma, «THE LANCET», 2018, 391, pp. 716 - 718 [Scientific article]
